DB18623InvestigationalCell transplant therapies
C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
- Mechanism
- Curator reviewed
Pharmacologically active on B-lymphocyte antigen CD20 and B-lymphocyte antigen CD19
- Also known as
- an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR · autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor targeting CD19 and CD20
- Code names
- C-CAR039
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with Prizloncabtagene autoleucel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account